Published on
Last updated on
China healthcare market update webinar - 2021 report
China healthcare market update webinar was held on December 15, 2021, by Cisema with the EU SME Centre and the China-Britain Business Council. The webinar provided an overview of the China regulatory updates for medical devices.
Webinar: Report Launch – The Healthcare Market in China (2021 Update)
The Healthcare Market in China (2021 Update) report provided an overview of the healthcare sector in China to cover the following topics:
• Key factors and drivers that are shaping the sector in China
• Analysis of China’s healthcare providers
• Up-to-date information on the market, regulations, key players and market entry requirements for three subsectors: (i) pharmaceuticals; (ii) medical devices; and (iii) healthcare services
• Main opportunities, challenges and key success factors for European SMEs
In addition, since the new Medical Device Regulations came into effect on June 1, 2021, the webinar further illustrated medical device classification on the NMPA regulations as well as medical devices registration procedure and the procurement policies, by Cisema, who is specialised in product registration in China.
Further information
Cisema’s team of regulatory experts regularly present in medtech, cosmetics, and pharmaceutical webinars to share insights and solutions for overcoming the most common regulatory hurdles in China.
Contact Cisema if there are any questions regarding NMPA registration or regulatory affairs in China.
GET IN TOUCH
Connect with Cisema
With more than 20 years of experience and a team of over 100 specialists, Cisema helps global companies achieve compliance across Asia Pacific with confidence and accelerate market entry.
Stay Informed with Monthly News and Analysis
Stay informed with the latest regulatory changes, expert insights, and market opportunities across APAC, delivered straight to your inbox.
Related News
China Expands MRI Registration Requirements Under New 2026 Review Guideline
Manufacturers seeking MRI registration in China must meet expanded technical, software, and validation requirements.
China CMDE Releases New Review Documents for Oncology NGS & HLA-B*58:01 Reagents
The new documents clarify expectations for Tier III variants, companion diagnostic clinical evaluation, tissue and plasma registration, and HLA-B*58:01 analytical validation.
Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites
As of July 1, 2026, Taiwan has completed its cosmetic GMP rollout, extending mandatory ISO 22716-based manufacturing standards to nearly all cosmetic factories